The Anti‐Metastatic Action of Oxyresveratrol via Suppression of Phosphoryl‐ ERK /‐ PKCα ‐Mediated Sp1/ MMP1 Signaling in Human Renal Carcinoma Cells
Environmental Toxicology · 2024
DOI: 10.1002/tox.24400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Environmental Toxicology, 2024. Verfasst von Tsai-Kun Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan. Hauptthemen laut MEDLINE: Protein Kinase C-alpha, Sp1 Transcription Factor, Kidney Neoplasms, Carcinoma, Renal Cell. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Tungs' Taichung Metro Harbor Hospital Taichung, Taiwan, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation.
Abstract (Originalsprache)
Oxyresveratrol (OxyR) exerts biological and pharmacological effects in a variety of tumor cells, including antioxidant action, antitumor activity, and proapoptotic effects. However, the regulation of targeted signaling pathways by OxyR and the mechanism underlying these effects in human renal cell carcinoma (RCC) have been less studied. We observed that OxyR at noncytotoxic doses did not affect the growth of human RCC cells or normal kidney HK2 cells. OxyR inhibited ACHN and Caki‐1 cell migration and invasion through targeting matrix metalloproteinase 1 (MMP1) expression. Analysis of clinical databases showed that high MMP1 expression is associated with lower overall survival (OS) in these cancers ( p < 0.01). OxyR significantly inhibited the mRNA and protein expression of Sp1. Furthermore, luciferase assay results showed that OxyR inhibited Sp1 transcriptional activity. Additionally, OxyR preferentially suppressed the activation of ERK and PKCα. Treatment with U0126 (MEK inhibitor) or G06976 (PKCα inhibitor) clearly decreased Sp1 and MMP1 expression and inhibited RCC cell migration and invasion. In conclusion, OxyR may be a potential antitumor therapy for the inhibition of migration and invasion by controlling p‐ERK/Sp1 and p‐PKCα/Sp1‐mediated MMP1 expression in RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan.
- Division of Renal Medicine, Tungs' Taichung Metro Harbor Hospital, Taichung, Taiwan.
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan.
- School of Medicine, Chung Shan Medical University, Taichung, Taiwan.
- Division of Nephrology, Department of Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.
ORCID-Profile: Yi-Hsien Hsieh
Förderung
- Tungs' Taichung Metro Harbor Hospital Taichung, Taiwan
- Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan
- Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Zitieren
APA
Wu, T. K., Hsieh, Y. H., Hung, T. W., Lin, Y. C., Lin, C. L., Liu, Y. J., Pan, Y. R., & Tsai, J. P. (2024). The Anti‐Metastatic Action of Oxyresveratrol via Suppression of Phosphoryl‐ ERK /‐ PKCα ‐Mediated Sp1/ MMP1 Signaling in Human Renal Carcinoma Cells. Environmental Toxicology. https://doi.org/10.1002/tox.24400
Vancouver
Wu TK, Hsieh YH, Hung TW, Lin YC, Lin CL, Liu YJ, et al. The Anti‐Metastatic Action of Oxyresveratrol via Suppression of Phosphoryl‐ ERK /‐ PKCα ‐Mediated Sp1/ MMP1 Signaling in Human Renal Carcinoma Cells. Environmental Toxicology. 2024. doi:10.1002/tox.24400
BibTeX
@article{Wu2024,
author = {Wu, Tsai-Kun and Hsieh, Yi-Hsien and Hung, Tung-Wei and Lin, Yi-Chen and Lin, Chia-Liang and Liu, Yu-Jou and Pan, Ying-Ru and Tsai, Jen-Pi},
title = {The Anti‐Metastatic Action of Oxyresveratrol via Suppression of Phosphoryl‐ ERK /‐ PKCα ‐Mediated Sp1/ MMP1 Signaling in Human Renal Carcinoma Cells},
journal = {Environmental Toxicology},
year = {2024},
doi = {10.1002/tox.24400}
}
EUVIMED